References
- Kocijančič A. Smernice za odkrivanje in zdravljenje osteoporoze. Zdrav Vestn. 2002;71:571.
- Prevention and management of osteoporosis: report of a WHO Scientific Group. WHO Technical Report Series; 921. Geneva: World Health Organization, 2003.
- Riggs BL, Melton LJ, Robb RA, Camp JJ, Atkinson EJ, McDaniel L, et al. A population-based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult women and men. J Bone Miner Res. 2008;23:205-14.17937534
- Lindsay R. Prevention and treatment of osteoporosis. Lancet. 1993;341:801-5.809600910.1016/0140-6736(93)90571-W
- Franič D. New aspects in diagnosis and treatment of osteoporosis. Zdrav Vestn. 2009;78:143-50.
- Kocjan T, Preželj J, Pfeifer M, Jensterle Sever M, Čokolič M, Zavratnik A. Smernice za odkrivanje in zdravljenje osteoporoze. Zdrav Vestn. 2013;82:207-17.
- Bolland MJ, Grey A, Reid IR. Should we prescribe calcium or vitamin D supplements to treat or prevent osteoporosis? Climacteric. 2015;18(Suppl 2):22-31.10.3109/13697137.2015.109826626473773
- Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA. 2003;290:1729-38.10.1001/jama.290.13.172914519707
- Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SAA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004;91:1701-12.
- Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;88:321-33.
- Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297:1465-77.17405972
- Kocjan T, Franič D. Osteoporoza in nadomestno hormonsko zdravljenje. Zdrav Vestn. 2008;77(Suppl 3):43-8.
- de Villiers TJ. The role of menopausal hormone therapy in the management of osteoporosis. Climacteric. 2015; 18(Suppl 2):19-21. 10.3109/13697137.2015.1099806.26474003
- Baber RJ, Panay N, Fenton A, IMS Writing Group. 2016 IMS recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19:109-50. 10.3109/13697137.2015.1129166.26872610
- Kanis JA, Harvey NC, Johansson H, Oden A, Leslie WD, McCloskey EV. FRAX and fracture prediction without bone mineral density. Climacteric. 2015; 18(Suppl 2):2-9. 10.3109/13697137.2015.1092342.26489076
- Kanis JA, Johnel O. Requirements for DXA for the management of osteoporoisi in Europe. Osteoporos Int. 2005;16:229-38.1561899610.1007/s00198-004-1811-2
- Komadina R, Senekovič V, Dolenc I, Andoljšek M,Grabljevec K, Venišek K, et al. Priporočila za zdravljenje zloma kolka v Sloveniji. Zdrav Vestn. 2012;81:183-92.
- Kocjan T. Zlomkolka – najpomembnejši zaplet ostoporoze. ISIS. 2010;19:64-6.
- Ilic Stojanovic M, Vuceljic M, Lazovic M, Gajic N, Radosavljevic D, Nikolic A, et al. Bone mineral density at different sites and vertebral fractures in Serbian postmenopausal women. Climacteric. 2017;20:37-43. 10.1080/13697137.2016.1253054.27860483
- Rentero ML, Carbonell C, Casillas M, Bejar MG, Berenguer R. Risk factors for osteoporosis and fractures in postmenopausal women between 50 and 65 years of age in a primary care setting in Spain: a questionnaire. Open Rheumatol J. 2008;2:58-63. 10.2174/1874312900802010058.
- Thomas CC, Zeytinoglu M. Primary care endocrinology in the adult woman. Obstet Gynecol Clin North Am. 2016;43:325-46. 10.1016/j.ogc.2016.01.005.27212095